<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603847</url>
  </required_header>
  <id_info>
    <org_study_id>ALK-OBS</org_study_id>
    <nct_id>NCT03603847</nct_id>
  </id_info>
  <brief_title>Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma</brief_title>
  <official_title>Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H么pital Necker-Enfants Malades</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondation ARC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the prognostic value on the complete metabolic response rate
      (MCR), the incidence of relapse / progression, the Progression Free Survival (PFS) and the
      Overall Survival (OS).

        -  at diagnosis

        -  after the first cycle of CHOEP (early evaluation)

        -  at the end of treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ALK-positive anaplastic large cell (anaplastic large-cell lymphoma, ALCL) is a rare adult
      disease for which almost all published studies are retrospective. The overall survival (OS)
      at 5 years varies from 70 to 87%. A recent international pooled analysis showed that the
      International Prognostic Index (IPI) had good predictive value for the PFS and the OS.

      In children, new prognostic factors have been identified: the titre of circulating anti-ALK
      antibodies (inverse correlation between the antibody titre and the prognosis), the detection
      of a NPM-ALK transcript in the blood at diagnosis (minimal disseminated disease, MDD);
      correlation between MDD positivity and pejorative prognosis) and its minimal residual disease
      (MRD), and the histological subtype (common versus small cells / lymphohistiocytic).

      The predictive value of the oncogenic profile of ALK-positive ALCL and circulating tumor DNA
      will be studied in this study.

        -  At diagnosis (before starting treatment):

        -  Cycle 2 Day 1 (before starting cycle 2 treatment):

        -  At the end of treatment evaluation:

           40 patients treated with 6 cycles of CHOEP every 3 weeks and 1 lumbar puncture at
           diagnosis with intrathecal prophylaxis with methotrexate will be included prospectively.

      During a 2-year period, relapses / progressions and patient deaths will be monitored for the
      calculation of the incidence of relapse / progression, progression free survival (PFS) and
      overall survival (OS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2018</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prognostic value of biological parameters on the complete metabolic response rate (MCR)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of biological parameters on the complete metabolic response rate (MCR)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of biological parameters on the complete metabolic response rate (MCR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of biological parameters on the incidence of relapse</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of biological parameters on the incidence of relapse</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of biological parameters on the incidence relapse</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of biological parameters on the Progression Free Survival (PFS)</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of biological parameters on the Progression Free Survival (PFS)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of biological parameters on the Progression Free Survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of biological parameters on the Overall Survival (OS)</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of biological parameters on the Overall Survival (OS)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of biological parameters on the Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Anaplastic Large Cell Lymphoma, ALK-Positive</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, constitutional DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult Anaplastic large-cell lymphoma ALK+
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Over 18 years old Diagnosed with Anaplastic large-cell lymphoma ALK+

        Planned treatment : 6 cycles of CHOEP 21

        Planned lumbar puncture at diagnosis or at the first cycle with intrathecal prophylaxis
        with methotrexate (15 mg) at the first cycle

        Planned interim positron emission tomograph (PET)-scan after 3 cycles of treatment and at
        the end of treatment according to the center standard of care

        Exclusion Criteria:

        Involvement of the central nervous system

        Intent of Autologous stem-cell transplant in first line
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David SIBON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H么pital Necker-Enfants Malades</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fanny CHERBLANC, PhD</last_name>
    <phone>+33 (0)4 27 01 27 17</phone>
    <email>fanny.cherblanc@lysarc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens - H么pital Sud</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghandi DAMAJ, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU d'Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien BAILLY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jehan DUPUIS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remy GRESSIN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - H么pital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck MORSCHHAUSER, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reda BOUABDALLAH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - H么pital Saint Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Thieblemont, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - H么pital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Sibon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Centre Fran莽ois Magendie</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamal BOUABDALLAH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre B茅nite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel BACHY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - H么pital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roch HOUOT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herv茅 TILLY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc-Matthieu Fornecker, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lo茂c YSEBAERT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre FEUGIER</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Sibon D, Fournier M, Bri猫re J, Lamant L, Haioun C, Coiffier B, Bologna S, Morel P, Gabarre J, Hermine O, Sonet A, Gisselbrecht C, Delsol G, Gaulard P, Tilly H. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. J Clin Oncol. 2012 Nov 10;30(32):3939-46. doi: 10.1200/JCO.2012.42.2345. Epub 2012 Oct 8.</citation>
    <PMID>23045585</PMID>
  </reference>
  <reference>
    <citation>Damm-Welk C, Mussolin L, Zimmermann M, Pillon M, Klapper W, Oschlies I, d'Amore ES, Reiter A, Woessmann W, Rosolen A. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2014 Jan 16;123(3):334-7. doi: 10.1182/blood-2013-09-526202. Epub 2013 Dec 2.</citation>
    <PMID>24297868</PMID>
  </reference>
  <reference>
    <citation>Damm-Welk C, Pillon M, Woessmann W, Mussolin L. Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK. Front Biosci (Schol Ed). 2015 Jun 1;7:205-16. Review.</citation>
    <PMID>25961696</PMID>
  </reference>
  <reference>
    <citation>Lamant L, McCarthy K, d'Amore E, Klapper W, Nakagawa A, Fraga M, Maldyk J, Simonitsch-Klupp I, Oschlies I, Delsol G, Mauguen A, Brugi猫res L, Le Deley MC. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol. 2011 Dec 10;29(35):4669-76. doi: 10.1200/JCO.2011.36.5411. Epub 2011 Nov 14.</citation>
    <PMID>22084369</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

